Related Experiment Video
Updated: May 30, 2026
10:30
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy
Aurélie Goyenvalle1, Kay E Davies
1MRC Functional Genomics Unit, Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK. aurelie.goyenvalle@dpag.ox.ac.uk
Skeletal Muscle
|July 30, 2011
Summary
Antisense oligonucleotides show promise for Duchenne muscular dystrophy by modulating gene expression. Recent clinical trials utilize exon skipping, but delivery and regulatory challenges persist for effective oligonucleotide therapeutics.
Area of Science:
- Molecular Medicine
- Genetics
- Biotechnology
Background:
- Antisense oligonucleotides (ASOs) are short nucleic acids targeting messenger RNAs.
- ASOs offer therapeutic potential by modulating splicing or inhibiting protein translation.
- Despite over 20 years of development, ASO therapeutics face significant hurdles.
Purpose of the Study:
- To review recent advancements in ASO-based therapies for Duchenne muscular dystrophy (DMD).
- To discuss ongoing clinical trials employing ASO exon skipping for DMD.
- To highlight challenges and future directions for ASO therapies in DMD.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Focus on exon skipping strategies for Duchenne muscular dystrophy.
- Analysis of therapeutic outcomes, delivery methods, and regulatory considerations.
Main Results:
- ASO-based exon skipping has shown recent therapeutic promise for DMD.
- Clinical trials are actively investigating ASO efficacy in DMD patients.
- Progress has been made, but challenges remain for widespread ASO therapeutic adoption.
Conclusions:
- ASO therapies, particularly exon skipping for DMD, are advancing.
- Successful implementation requires overcoming delivery and regulatory obstacles.
- Continued research is crucial for realizing the full potential of ASO therapeutics.
More Related Videos
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...